NIFTY 50

Here’s what to expect from Glenmark Pharma’s Q3FY19 numbers

Updated : February 14, 2019 09:54 AM IST

This time, in Q3FY19, expect a revenue growth of 15 percent odd for Glenmark Pharma with EBITDA growth of around 36 percent. Thus, there should be some amount of improvement in the margins on a year-on-year (YoY) basis to 17.4 versus 14.6 percent with the profit at around Rs 225 crore odd. However, the profit is going to escalate on the back of low base as the profit was down 75 percent during Q3FY18.

The US business would be the most important thing to watch out for this company because in Q3FY18, the US business was down 40 percent on YoY basis. Therefore, the low base has aided them in Q2 of FY19 where the US business had picked up to 11.4 percent growth after declining for 4 quarters. So, the hope is that the kind of momentum is going to sustain for Glenmark in this quarter as well.

Furthermore, US and India will be the key focus markets for the company, with regards to out licensing opportunities where they have already done 3-4 regional out licensing deals in the quarter gone by.

primo org
Have you signed up for Primo, our daily newsletter?
It has all the stories and data on the market, business, economy and tech that you need to know.
cnbc two logos
To keep watching CNBC-TV18, India's No. 1 English Business News Channel, call your Cable or DTH Operator and subscribe now for just Rs. 4 per month. You can also subscribe to CNBC-TV18 Prime HD for Re 1/- per month.Find out more
Live TV